Creating a comprehensive drug development plan

Providing regulatory support in China for a new compound

Achieving sponsor goals with efficient end-to-end solutions

The power of real-world data in clinical development and post-market activities

Strategic considerations when planning an externally controlled single-arm trial

Why literature reviews should be a key part of your evidence-generation strategy

Precision medicines for neurodegenerative disorders: optimizing clinical development

Precision medicine, a new paradigm of individualized treatment, is revolutionizing healthcare. This innovative approach utilizes lifestyle and environmental factors, molecular, cellular and image profiling, as well as genomic information to enable treatment and management of disease that is specialized and unique to a given patient.

Successfully delivering an ultra-rare disease clinical trial in a competitive landscape

Fortrea’s Diseases, Advanced Therapies and Pediatrics Team (RAPT) was selected to deliver a Phase III study for patients living with the ultra-rare disease limb-girdle muscular dystrophy type 2I (LGMD2I). Another sponsor was simultaneously recruiting LGMD2I patients, increasing the demand for a limited pool of qualified patients and experienced sites in an already difficult-to-recruit space.

Collaborative practices advance a rare ophthalmological disease clinical trial

Fortrea forged strong connections with sites and an advocacy group to create a high level of participant interest in a rare disease clinical trial. Learn how the team applied its ophthalmological, rare disease and operational expertise to ultimately surpass recruitment targets by more than ~20% of the sponsor’s original target—and help the sponsor achieve an orphan drug designation for their treatment.

Considerations for pediatric vaccine trials in developing countries